Patients with idiopathic pulmonary fibrosis (IPF) have a high risk of developing other health conditions, according to results of a study presented at the annual meeting of the American College of Chest Physicians (CHEST 2016), held in Los Angeles Oct. 22-26. The results were presented under the title “Longitudinal…
News
The effectiveness of long-term treatment with the anti fibrotic drug Esbriet (pirfenidone) for more than 3 years does not depend on the forced vital capacity (FVC) at baseline in patients with idiopathic pulmonary fibrosis (IPF), according to a clinical trial called RECAP (NCT00662038).
Esbriet (pirfenidone) can be used as a long-term therapy in idiopathic pulmonary fibrosis (IPF) patients with more severe loss of lung function, according to results presented at the American College of Chest Physicians (CHEST 2016), held in Los Angeles from Oct. 22–26. The findings were described in the oral presentation, “…
Results from two Phase 3 studies, known as the INPULSIS trials, further confirmed the efficacy of Ofev (nintedanib) to treat idiopathic pulmonary fibrosis (IPF) regardless of disease severity. The results, from post-hoc pooled analyses of the trials, were recently presented at the CHEST 2016 Annual Meeting, running in Los Angeles through Wednesday, Oct. 26.
Mesenchymal stem cells show considerable potential as a means of treating idiopathic pulmonary fibrosis (IPF), but numerous issues need to be resolved before a stem cell approach might benefit patients. The study, “Mesenchymal stem cells in the treatment of chronic lung disease,” published in the journal Respirology, also underscored…
‘Exhale, Mindfully Manage Your IPF’ is a new initiative co-sponsored by the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR), the Pulmonary Fibrosis Foundation, and the international biotechnology firm Genentech. The program’s aim is to help people living with idiopathic pulmonary fibrosis (IPF), and encourage…
The National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) awarded a seven-year grant worth $5.2 million to a team of researchers looking into the cellular and molecular mechanisms that promote lung regeneration, and aiming to develop therapies for children with hereditary lung diseases and adults with pulmonary fibrosis…
Today, Oct. 17, is the 11th annual World Day for Organ Donation and Transplantation. While medical advances have resulted in increasing numbers of transplants performed each year, the availability of donor organs is still not enough to fulfill the urgent needs of all those awaiting a transplant. One reason for the limited availability is that…
A rare form of immune T-cells promotes chronic inflammation and pulmonary fibrosis, researchers at the Johns Hopkins University School of Medicine found. Their discovery, made in a mice model of the disease, may lead to a new therapeutic target for lung fibrosis. The research report, “Deletion of mTORC1 activity in CD4+ T cells…
Statins provide beneficial effects, including decreased death risk, in a large and well-defined cohort of patients with idiopathic pulmonary fibrosis (IPF), according to an analysis of past studies. Findings were reported in the article “Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis,” recently published in…
